European Commission Withdraws EU Marketing Authorisation For Zinplava At Merck Sharp & Dohme B.V.’s Request After Permanent Discontinuation For Commercial Reasons

On October 20, 2026, the European Commission withdrew the marketing authorization for Zinplava (bezlotoxumab) at the request of Merck Sharp & Dohme B.V., which decided to permanently discontinue the product for commercial reasons. Zinplava was initially authorized in the EU on January 18, 2017, for preventing recurrence of Clostridium difficile infection in adults and received unlimited validity in 2021, with an extension for children granted in December 2023.